Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAF-4L6715 in Acute Respiratory Distress Syndrome
NCT06640777Phase 3Not yet recruiting
- Sponsor
- LEAF4Life
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liposomal transcrocetin in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by LEAF4Life. Primary endpoints: Days free from invasive mechanical ventilation at 30 days and All-Cause Mortality at 30 days. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
liposomal transcrocetin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06640777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640777.